Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of lufenuron nitenpyram in China. Welcome to wholesale bulk high quality lufenuron nitenpyram for sale here from our factory. Good service and reasonable price are available.
The combination therapy of lufenuron nitenpyram is an efficient prevention and control strategy for pet ectoparasites, especially fleas. Lufenuron belongs to the benzoylurea class of insect growth regulators. It interferes with insect epidermal development by inhibiting chitin synthesis, preventing egg hatching, but has no direct lethal effect on adult insects. Nitenpyram is a neonicotinoid neurotoxin that can rapidly block signal transduction in the insect nervous system, leading to paralysis and death of adult insects. When the two are used in combination, Nitenpyram controls the existing population density by rapidly knocking down adult insects, while Lufenuron blocks flea life cycle through long-term inhibition of reproduction, forming a synergistic effect of "quick acting+long-term".
Clinical studies have shown that this combination has significant effects in the prevention and control of fleas in dogs and cats: it can reduce more than 97.3% of surface fleas within 7 days and maintain the prevention and control effect for 3 months; At the same time, it has a sustained inhibitory effect on flea eggs and larvae in the home environment, reducing the number of fleas by 89.5% within 28 days and completely eliminating them within 90 days. This scheme is particularly suitable for areas with seasonal flea outbreaks, significantly reducing the risk of repeated infections by covering the adult, larval, and egg stages. Although its effectiveness in the prevention and control of wildlife diseases is limited, optimizing the dosage or formulation of drugs may enhance its application potential.
Our product
Additional information of chemical compound:
Nitenpyram COA
Mechanism of Combined Synergistic Insecticidal Action
Fleas are among the most prevalent ectoparasites of companion animals. Their complete life cycle and strong environmental adaptability often result in incomplete control, high relapse rates, and persistent skin damage to hosts when a single parasiticide is used. Lufenuron nitenpyram form a classic combination for companion-animal flea control. Their enhanced flea-killing effect does not rely on simple additive toxicology; instead, divergent target sites, pharmacological profiles, and action timelines enable segmented closed-loop control across the entire flea life cycle. Complementary dosing characteristics and resistance management further improve overall flea population suppression.
Segmented Closed-Loop Control Based on the Flea Life Cycle (Core Synergistic Mechanism)
Fleas are holometabolous parasites with four developmental stages: adult, egg, larva, and pupa. These stages differ markedly in habitat, physiology, and drug susceptibility, so no single active ingredient can cover the full life cycle. Nitenpyram targets adult fleas, while lufenuron targets eggs and larvae. Together they establish a dual-line defense: rapid immediate knockdown plus sustained population suppression. This two-pronged blockade of key reproductive nodes underpins their core synergistic logic.
Key Challenges in Controlling the Complete Flea Life Cycle
The flea life cycle operates as a self-sustaining closed loop. Adults parasitizing pets ingest blood for nutrition, mate, and continuously lay eggs that fall into carpets, sofas, bedding, and other environmental substrates. Under suitable temperature and humidity, eggs hatch into larvae, which feed on organic debris and adult flea feces. Mature larvae spin cocoons and pupate; the pupal stage is the most tolerant dormant phase, resilient to most parasiticides and environmental stressors. When conditions improve, new adults emerge, re-infest hosts, and initiate another reproductive cycle.
Three characteristics explain recurrent failure of single-agent regimens: the lack of effective pupicidal agents, cryptic environmental immature stages, and rapid adult reproduction.
Nitenpyram: Immediate Control of On-Animal Adults
As a fast-acting neonicotinoid insecticide, nitenpyram acts on the nicotinic acetylcholine receptors of adult fleas and serves as an emergency rapid-control line. It readily penetrates the flea cuticle and disrupts neural transmission, causing hyper-excitation, muscle tetany, and death, thereby quickly eliminating existing on-host adults. Its value lies in two dimensions.
First, it rapidly stops biting damage: persistent flea feeding releases specific antigens that trigger flea allergy dermatitis (FAD), manifesting as erythema, pruritus, alopecia, and skin ulceration. By killing adults quickly, nitenpyram interrupts biting and antigen stimulation, relieving clinical pruritus and dermatitis. Second, it cuts off population expansion: blood-feeding female fleas on pets are the sole source of environmental eggs. Rapid adult knockdown drastically reduces egg output, lowers environmental egg deposition, and reduces future pressure from immature fleas.
Lufenuron: Long-Term Suppression of Environmental Immature Fleas
Lufenuron is an insect chitin synthesis inhibitor with no direct adulticidal activity. By interfering with insect chitin biosynthesis, it selectively suppresses flea egg hatching and larval development, forming a long-term population-suppression barrier. The drug persists in host skin lipids and acts after contact with environmental eggs and newly emerged larvae. It impairs chitin formation in the eggshell, lowering hatch rates and preventing many eggs from developing normally.
It also blocks chitin production during larval molting and growth; newly hatched larvae die from malformed exoskeletons and failed ecdysis, halting progression from larva to pupa and adult.Even if a small number of resilient pupae emerge and lay eggs, the next generation of eggs and larvae cannot develop normally under lufenuron exposure and cannot establish new breeding populations. This continuously reduces the environmental flea reservoir and addresses re-infestation after adult fleas are eliminated.
Closed-Loop Synergy Across the Life Cycle
The core advantage of the combination is division of labor and closed-loop population control.
Nitenpyram clears existing adults and curtails new egg input, resolving acute on-host infestation and ongoing reproduction. Lufenuron inhibits environmental egg hatching and eliminates larvae to break developmental chains, removing hidden environmental reservoirs. One addresses immediate adult burden; the other suppresses long-term population growth. Together they compress flea numbers at sequential stages and break the cyclic life cycle. However, the system has a clear blind spot: neither compound kills pupae. Protected by cocoons, pupae evade treatment and remain the main reason occasional adult emergence is observed clinically.
Complementary Synergy in Pharmacology and Dosing Profiles
Nitenpyram and lufenuron differ fundamentally in physicochemical properties, systemic absorption and elimination, and tissue persistence. This creates a dosing paradigm combining short-term pulsed intervention for acute symptoms and long-term steady-state population control, overcoming inherent limitations of monotherapy and improving practical clinical efficacy.
Nitenpyram: Short-Acting Pulsed Profile and Limitations of Monotherapy
Nitenpyram is highly water-soluble. After oral administration, it is rapidly absorbed from the gastrointestinal tract, enters systemic circulation, and reaches fleas feeding on the host, producing fast onset. It follows a well-defined clearance pathway, primarily renal excretion in urine with minimal tissue accumulation, making it a typical short-acting pulsed parasiticide. Because its activity depends on systemic blood levels rather than cutaneous lipid reservoirs, its efficacy is stable regardless of bathing, swimming, or rain exposure.The major limitation of monotherapy is its short duration of action: it kills only existing adults and has no activity against environmental eggs, larvae, or pupae.
Once drug levels decline, residual pupae continuously emerge and re-infest pets, causing repeated outbreaks and preventing sustained control. It also cannot mitigate delayed pressure from immature fleas already developing in the environment, leading to poor long-term population suppression.
Lufenuron: Long-Term Depot Profile and Limitations of Monotherapy
Lufenuron is highly lipophilic, in sharp contrast to nitenpyram. After dosing, it is not rapidly metabolized but sequestered in subcutaneous adipose tissue to form a stable depot. Slow release from fat delivers the drug through cutaneous lipids to the skin and hair surface, enabling prolonged steady-state exposure.
This allows sustained activity against flea eggs and larvae contacting the pet, suppressing population development over time.Nevertheless, monotherapy has important clinical drawbacks: lufenuron does not kill adults. Existing fleas on the pet continue biting and reproducing, so pruritus and dermatitis are not rapidly relieved, compromising owner satisfaction. Continued egg laying replenishes environmental reservoirs, so symptom onset is delayed and immediate relief is lacking.
Synergistic Complementarity in Combined Dosing
Lufenuron nitenpyram resolves the key weaknesses of single agents and creates optimal temporal complementarity.
Nitenpyram provides rapid, reliable pulsed knockdown to eliminate adults, relieve clinical signs, and stop immediate egg laying, addressing the slow onset and persistent biting seen with lufenuron alone. Lufenuron, via adipose depot and cutaneous persistence, continuously suppresses environmental immature fleas and fills the efficacy gap after nitenpyram wanes. Short-acting control of acute symptoms plus long-acting suppression of recurrence balances early clinical performance and sustained population pressure, improving regimen completeness and practical utility.
Synergistic Resistance Management via Divergent Target Sites
Parasiticide resistance is a major cause of ectoparasiticide failure. Prolonged monotherapy imposes directional selection that favors target-site mutations and stable resistant populations. Lufenuron and nitenpyram belong to separate IRAC mode-of-action groups with fully independent pathways, creating a critical synergistic advantage for resistance mitigation and delaying the evolution of flea resistance.
Distinct Targets and Pathways
Under IRAC insecticide mode-of-action classification, nitenpyram is a nicotinic acetylcholine receptor agonist that disrupts flea neural transmission. Lufenuron is an insect growth inhibitor targeting chitin synthase CHS1 and blocking epidermal chitin formation. Their pathways, target proteins, and mechanisms do not overlap, which is the molecular basis for low risk of cross-resistance.
Resistance Avoidance in Combination Regimens
Continuous nitenpyram use selects for fleas with mutated nAChR receptors that reduce drug binding, generating nerve-target resistance. Continuous lufenuron use selects for fleas with CHS1 mutations that render developmental inhibition ineffective. A rational combined strategy uses intermittent pulsed nitenpyram for acute outbreaks rather than permanent exposure, lowering selection pressure at the nAChR target. Lufenuron provides sustained larval suppression and reduces amplification of mutant fleas. Alternation and division of labor avoid persistent directional selection on a single target, reduce the probability of resistance mutations spreading through the population, and extend the clinical lifespan of the formulation.
Prevention and treatment of pet ectoparasites
Prevention and Control of Fleas in Dogs and Cats:
In the field of veterinary medicine, the combination therapy of lufenuron nitenpyram has been widely used for flea control in dogs and cats. After oral administration, Lufenuron can be distributed throughout the body with adipose tissue, inhibiting the hatching of flea eggs; Nitenpyram can quickly kill adult insects and reduce flea bites. Research has shown that combination therapy can reduce the number of fleas on pet surfaces by over 97.3% within 7 days and maintain a preventive effect for up to 3 months. This plan is particularly suitable for areas with seasonal flea outbreaks.
Environmental flea control:
Fleas not only parasitize on the sur:face of pets, but also reproduce in their living environment. The combination therapy of Lufenuron and Nitenpyram can indirectly control flea larvae and eggs in the environment through drug residues in pet hair and feces. Experimental data shows that combination therapy can reduce the number of fleas in the home environment by 89.5% within 28 days and completely eliminate them within 90 days.
Prevention and Control of Wildlife Diseases
Prevention and control of canine plague in Black Tail Grassland:
In the prevention and control of wild animal epidemics, the combination of Lufenuron and Nitenpyram is used to control the fleas on the surface of grassland dogs (Cynomoys spp.) to reduce the transmission risk of pestis pestis. However, field experiments have shown that the combination therapy of conventional doses (75 mg Lufenon+6 mg Nitenpyram) has limited control effect on fleas in prairie dogs and mice, which may be related to the metabolic differences of the drugs in wild animals. Future research needs to explore higher dose or more frequent medication regimens.
Protection of Endangered Species:
For endangered species that rely on prairie dogs and rodents for food, such as black footed ferrets, controlling flea infections in their bodies is key to protecting population health. Although the current combination therapy regimen is not effective in the wild, optimizing the administration method (such as sustained-release formulations) or increasing the frequency of medication may improve the control effect on wild animal fleas.
Practical application cases of combination therapy
Pet Flea Prevention and Control Cases:
In a study in Florida, 35 dogs and cats infected with fleas were randomly divided into two groups: one group received a combination therapy of Lufenuron and Nitenpyram, and the other group received Lufenuron treatment alone. The results showed that the combination therapy group reduced the number of fleas on the surface of pets by 97.3% within 7 days and maintained this effect throughout the entire study period (90 days); The single drug group showed a rebound in flea numbers in the later stage. In addition, the flea population in the home environment of the combination therapy group decreased by 89.5% within 28 days and was completely eliminated within 90 days.
Cases of Wildlife Disease Prevention and Control:
In the project of grassland dog and mouse pestis prevention and control, researchers tried to use bait containing lufenuron nitenpyram to control fleas on the body surface of dog and mouse. However, field experiments have shown that the control effect of conventional doses of combination therapy on fleas in dogs and mice is limited, which may be related to the metabolic rate or behavioral habits of dogs and mice. Future research needs to explore higher dose or more frequent medication regimens.
Pharmacokinetic characteristics of combination therapy
Lufenuron mainly accumulates in adipose tissue after oral administration and maintains its long-lasting effect through slow release. It has a long half-life and can exert inhibitory effects on chitin synthesis in animals for several months. This characteristic makes it suitable as a long-acting preventive and therapeutic agent, but it may also lead to long-term residue of the drug in the body.
Nitenpyram is rapidly absorbed after oral administration, typically reaching a peak blood concentration within 1 hour and rapidly distributed throughout the body tissues. Its blocking effect on the nervous system can manifest within minutes, and it can knock down pests very quickly. However, Nitenpyram has a short half-life and is usually completely metabolized within 24 hours, so it needs to be used in combination with other long-acting agents to maintain its preventive and therapeutic effects.
The combination therapy of Lufenuron and Nitenpyram can achieve complementary pharmacokinetics. The rapid onset of Nitenpyram can quickly control pest density, while the long-term effect of Lufenuron can prevent pest population rebound. In addition, the metabolic pathways of the two are different in the body, and their combined use does not increase the risk of drug residue.
FAQ
What kind of drug is lufenuron?
+
-
Lufenuron is a benzoylurea insecticide. This class of insecticides was previously used on fruits to decrease damage by insects. Lufenuron (Program) has been used for prevention of flea infections in dogs and cats because it inhibits chitin synthesis.
What is lufenuron nitenpyram?
+
-
Provides extended flea protection for dogs and puppies. The only way to introduce a long-term IGR into the animal's environment, as sun rays break down IGR yard sprays within a day.
What is the difference between nitenpyram and lufenuron?
+
-
Pharmacological Category: Nitenpyram is a flea adulticide. Lufenuron is an insect development inhibitor. infestations, are combined to provide a FLEA MANAGEMENT SYSTEM™.
Hot Tags: lufenuron nitenpyram, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Methylergonovine Maleate Salt CAS 57432 61 8, Alizarin Red Powder CAS 130 22 3, lidocaine hydrochloride powder, tetramisole hydrochloride powder, Atropine Sulfate Monohydrate CAS 5908 99 6, Bicuculline CAS 485 49 4